nach oben

Erschienen in:

01.04.2010 | Original Research Article

Retinal function in patients treated with tamoxifen

verfasst von: Sung Eun Song Watanabe, Adriana Berezovsky, Márcia Motono, Paula Yuri Sacai, Josenilson Martins Pereira, Juliana Maria Ferraz Sallum, Luiz Henrique Gebrim, Solange Rios Salomão

Erschienen in: Documenta Ophthalmologica | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Tamoxifen, an effective treatment of breast cancer, has been shown to cause ocular toxic effects. The purpose of this study was to determine retinal toxicity by full-field and focal electroretinograms (ERGs) in patients treated with tamoxifen. Full-field and focal ERGs were obtained from three groups: Tamoxifen—14 females (47–72 years, mean 58.3 ± 9.1) with normal fundus, treated with tamoxifen from 2 to 37 months; No Treatment—10 females (39–65 years, mean 50.1 ± 8.7) with previous breast cancer diagnosis and before tamoxifen treatment; Control—13 normal female volunteers (41–81 years, mean 52.7 ± 12.1). Peak-to-peak amplitude and b-wave implicit time were measured and statistically analyzed. Mean peak-to-peak amplitudes and implicit time from full-field and focal ERGs were comparable for the three different groups. Low-dosage tamoxifen showed no retinotoxic effect assessed by full-field and focal ERG in this small group of women with breast cancer.

Gordon NH, Silverman P, Lasheen W, Meinert J, Siminoff LA (2007) Thirty-year follow-up of chemo-hormonal therapy in node-positive breast cancer. Breast Cancer Res Treat 102:301–312CrossRefPubMed

Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 352:930–942CrossRef

Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351:1451–1467CrossRef

Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER, Margolese R, Robidoux A, Shibata H, Terz J, Paterson AHG, Feldman MI, Farrar W, Evans J, Lickley L, Ketner M, Abramson N, Allegra JC, Beazley R, Berry J, Boatman KK, Carmichael D, Cruz AB Jr, Davies R, Deckers P, Desser R, Reese M, Economou S, Elias G, Feldman M, Foster RS, Frazier TG, Glass AG, Jochimsen P, Jubelirer S, Kardinal CG, Keyserlingk JR, Lerner HJ, Levick SN, Mahoney L, Mowry P, Nicola M, Oishi R, Pasquale D, Perrault D, Peters G, Poisson R, Pugh R, Robert N, Spector J, Sponzo R, Sterchi JM, Sutherland CM, Thiessen AR, Thirlwell M, Welling R, Wold H, Wozniak T (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumor. N Engl J Med 320:479–484PubMedCrossRef

Jordan VC (1995) Tamoxifen for breast cancer prevention. Proc Soc Exp Biol Med 208:144–149PubMed

Powles TJ (1997) Efficacy of tamoxifen as treatment of breast cancer. Semin Oncol 24(Suppl 1):SI48–SI54

Meier CR, Jick H (1998) Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 45:608–612CrossRefPubMed

Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609–1618CrossRefPubMed

Kaiser-Kupfer MI, Lippman ME (1978) Tamoxifen retinopathy. Cancer Treat Rep 62:315–320PubMed

10.

Kaiser-Kupfer MI, Kupfer C, Rodrigues M (1981) Tamoxifen retinopathy: a clinicopathologic report. Ophthalmology 88:89–93PubMed

11.

McKeown CA, Swartz M, Blom J, Maggiano JM (1981) Tamoxifen retinopathy. Br J Ophthalmol 65:177–179CrossRefPubMed

12.

Beck M, Mills PV (1979) Ocular assessment of patients treated with tamoxifen. Cancer Treat Rep 63:1833–1834PubMed

13.

Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, Petroutsos G (1992) Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. Cancer 69:2961–2964CrossRefPubMed

14.

Bernstein PS, DellaCroce JT (2007) Diagnostic & therapeutic challenges. Tamoxifen toxicity. Retina 27:982–988CrossRefPubMed

15.

Cronin BG, Lekich CK, Bourke RD (2005) Tamoxifen therapy conveys increased risk of developing a macular hole. Int Ophthalmol 26:101–105CrossRefPubMed

16.

Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ (1994) Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol 117:772–775PubMed

17.

Tang R, Shields J, Schiffman J, Li H, Locher D, Hampton J, Prager T, Pardo G (1997) Retinal changes associated with tamoxifen treatment for breast cancer. Eye 11:295–297PubMed

18.

Noureddin BN, Seoud M, Bashshur Z, Salem Z, Shamseddin A, Khalil A (1999) Ocular toxicity in low-dose tamoxifen: a prospective study. Eye 13:729–733PubMed

19.

Gianni L, Panzini I, Li S, Gelber RD, Collins J, Holmberg SB, Crivellari D, Castiglione-Gertsch M, Goldhirsch A, Coates AS, Ravaioli A, International Breast Cancer Study Group (IBCSG) (2006) Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer 106:505–513CrossRefPubMed

20.

Salomão SR, Watanabe SE, Berezovsky A, Motono M (2007) Multifocal electroretinography, color discrimination and ocular toxicity in tamoxifen use. Curr Eye Res 32:345–352CrossRefPubMed

21.

Beck M, Mills PV (1979) Ocular assessment of patients treated with tamoxifen. Cancer Treat Rep 63:1833–1834PubMed

22.

Longstaff S, Sigurdsson H, O′Keeffe M, Ogston S, Preece P (1989) A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma. Eur J Cancer Clin Oncol 25:1805–1808CrossRefPubMed

23.

Easterbrook M (1988) Ocular effects and safety of antimalarial agents. Am J Med 14:23–29CrossRef

24.

Zrenner E (2006) Drug side effects and toxicology of the visual system. In: Heckenlively JR (ed) Principles and practice of clinical electrophysiology of vision, 2nd edn. Cambridge, London, pp 655–662

25.

Kuchenbecker J, Pump-Schmidt C, Olbricht S, Weise W, Behrens-Baumann W (2001) Electrophysiological studies in breast carcinoma patients with tamoxifen retinopathy. Ophthalmologe 98:81–85CrossRefPubMed

26.

Ritter C, Renner AB, Wachtlin J, Bechrakis NE, Krause L (2008) Tamoxifen retinopathy: a case series of clinical and functional data. Ophthalmologe 105:544–549CrossRefPubMed

27.

Gerner EW (1989) Ocular toxicity of tamoxifen. Ann Ophthalmol 21:420–423PubMed

28.

Bentley CR, Davies G, Aclimandos WA (1992) Tamoxifen retinopathy: a rare but serious complication. BMJ 304:495–496CrossRefPubMed

29.

Berezovsky A, Moraes NS, Nusinowitz S, Salomão SR (2003) Standard full-field electroretinography in healthy preterm infants. Doc Ophthalmol 107:243–249CrossRefPubMed

30.

Engelke M, Tykhonova S, Zorn-Kruppa M, Diehl H (2002) Tamoxifen induces changes in the lipid composition of the retinal pigment epithelium cell line D407. Pharmacol Toxicol 91:13–21CrossRefPubMed

31.

Toimela T, Tähti H, Salminen L (1995) Retinal pigment epithelium cell culture as a model for evaluation of the toxicity of tamoxifen and chloroquine. Ophthalmic Res 27:150–153CrossRefPubMed

32.

Gualino V, Cohen SY, Delyfer MN, Sahel JA, Gaudric A (2005) Optical coherence tomography findings in tamoxifen retinopathy. Am J Ophtahlmol 140:757–758CrossRef

33.

Eisner A, Austin DF, Samples JR (2004) Short wavelength automated perimetry and tamoxifen use. Br J Ophthalmol 88:125–130CrossRefPubMed

Titel: Retinal function in patients treated with tamoxifen
verfasst von: Sung Eun Song Watanabe
Adriana Berezovsky
Márcia Motono
Paula Yuri Sacai
Josenilson Martins Pereira
Juliana Maria Ferraz Sallum
Luiz Henrique Gebrim
Solange Rios Salomão
Publikationsdatum: 01.04.2010
Verlag: Springer-Verlag
Erschienen in: Documenta Ophthalmologica / Ausgabe 2/2010
Print ISSN: 0012-4486
Elektronische ISSN: 1573-2622
DOI: https://doi.org/10.1007/s10633-009-9203-8

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Retinal function in patients treated with tamoxifen

Abstract

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2010

Can central hexagon peak latency provide a clue to fixation within the mfERG

Pattern electroretinogram optimized for glaucoma screening (PERGLA) and retinal nerve fiber thickness in suspected glaucoma and ocular hypertension

Spatial distributions of on- and off-responses determined with the multifocal ERG

Macular function in tilted disc syndrome

A comparison of multifocal ERG and frequency domain OCT changes in patients with abnormalities of the retina

Correlation between functional and anatomical assessments by multifocal electroretinography and optical coherence tomography in central serous chorioretinopathy

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde